The study authors randomly assigned 17,802 healthy men and women with LDL of less than 130 mg/dL (3.4 mmol/L) and high-sensitivity CRP of 2.0 mg/L or higher to receive rosuvastatin, 20 mg per day, or placebo.
The rates of venous thromboembolism were 0.18 and 0.32 event per 100 person-years of follow-up in the rosuvastatin and placebo groups, respectively (hazard ratio with rosuvastatin, 0.57; P=0.007).
The rates of pulmonary embolism were 0.09 in the rosuvastatin group and 0.12 in the placebo group (hazard ratio, 0.77; 95% CI, 0.41 to 1.45; P=0.42), whereas the rates of deep-vein thrombosis only were 0.09 and 0.20, respectively (hazard ratio, 0.45; P=0.004).
In this trial of apparently healthy persons, rosuvastatin significantly reduced the occurrence of symptomatic venous thromboembolism by 43% (DVT and PE).
A Randomized Trial of Rosuvastatin in the Prevention of Venous Thromboembolism. MEJM, March 29, 2009 (10.1056/NEJMoa0900241).